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Mitochondrial diseases include a group of maternally
inherited genetic disorders caused by mutations in
mtDNA. In most of these patients, mutated mtDNA
coexists with wild-type mtDNA, a situation known as
mtDNA heteroplasmy. Here, we report on a strategy
toward preventing germline transmission of mito-
chondrial diseases by inducing mtDNA heteroplasmy
shift through the selective elimination of mutated
mtDNA. As a proof of concept, we took advantage of
NZB/BALB heteroplasmic mice, which contain two
mtDNA haplotypes, BALB and NZB, and selectively
prevented their germline transmission using either
mitochondria-targeted restriction endonucleases or
TALENs. In addition, we successfully reduced human
mutated mtDNA levels responsible for Leber’s hered-
itary optic neuropathy (LHOND), and neurogenicmus-
cleweakness, ataxia, and retinitispigmentosa (NARP),
in mammalian oocytes using mitochondria-targeted
TALEN (mito-TALENs). Our approaches represent a
potential therapeutic avenue for preventing the trans-
generational transmission of human mitochondrial
diseases caused by mutations in mtDNA.
INTRODUCTION
Mitochondria are double-membrane cellular organelles of
bacterial origin that play fundamental roles in multiple cellularprocesses including energy production, calcium homeostasis,
cellular signaling, and apoptosis (Dyall et al., 2004).Mitochondria
contain their own mtDNA encoding 13 polypeptides of the mito-
chondrial respiratory chain as well as tRNAs and rRNAs neces-
sary for their synthesis (Anderson et al., 1981). mtDNA is present
in multiple copies per cell, ranging from approximately 1,000
copies in somatic cells to several 100,000 copies in oocytes,
with an average 1–10 copies per organelle (Shoubridge and
Wai, 2007). In contrast to nuclear DNA, mtDNA is exclusively
transmitted through maternal inheritance. Diseases resulting
from mitochondrial dysfunction caused by mtDNA mutations
affect 1 in 5,000 children (Haas et al., 2007), and it is estimated
that 1 in 200 women could be a mitochondrial disease carrier.
Due to the fundamental role of mitochondria in energy produc-
tion, mitochondrial diseases correlate with degeneration of tis-
sues and organs with high-energy demands. This leads tomyop-
athies, cardiomyopathies, and encephalopathies, among other
phenotypes (Taylor and Turnbull, 2005). Currently, there is no
cure for mitochondrial diseases. Genetic counseling and pre-im-
plantation genetic diagnosis (PGD) represent the only therapeu-
tic options for preventing transmission of mitochondrial diseases
caused by mtDNA mutations. However, due to the non-Mende-
lian segregation of mtDNA, PGD can only partially reduce the risk
of transmitting the disease (Brown et al., 2006). Moreover, anal-
ysis of multiple blastomeres may compromise embryo viability.
Recently, mitochondrial replacement techniques by spindle,
pronuclear, or polar body genome transfer into healthy enucle-
ated donor oocytes or embryos have been reported (Craven
et al., 2010; Paull et al., 2013; Tachibana et al., 2013; Wang
et al., 2014). Application of these techniques implies combining
genetic material from three different individuals, which hasCell 161, 459–469, April 23, 2015 ª2015 Elsevier Inc. 459
raised ethical, safety, and medical concerns (Hayden, 2013;
Vogel, 2014). Therefore, alternative and complementary ap-
proaches that alleviate or eliminate these concerns should be
investigated when devising feasible clinical paths toward pre-
venting the transmission of mitochondrial diseases caused by
mtDNA mutations.
Due to the thousands of copies of mtDNA contained within a
cell, the levels of mutated mtDNA can vary. The term homo-
plasmy refers to the presence of a single mtDNA haplotype
in the cell, whereas heteroplasmy refers to the coexistence of
more than one mtDNA haplotype. When the percentage of
mutated mtDNA molecules exceeds a threshold that compro-
mises mitochondrial function, a disease state may ensue (Tay-
lor and Turnbull, 2005; Wallace and Chalkia, 2013). Threshold
levels for biochemical and clinical defects are generally in the
range of 60%–95% mutated mtDNA depending on the severity
of the mutation (Russell and Turnbull, 2014). Changes in the
relative levels of heteroplasmic mtDNA can be referred to as
mtDNA heteroplasmy shifts. Despite the fact that mitochondria
possess all the necessary machinery for homologous recombi-
nation and non-homologous end joining, they do not seem to
represent the major pathway for mtDNA repair in mammalian
mitochondria (Alexeyev et al., 2013). Previous studies have
demonstrated that the relative levels of mutated and wild-
type mtDNA can be altered in patient somatic cells containing
the m.8993T>G mtDNA mutation responsible for the NARP and
MILS syndromes, where elimination of mutated mtDNA led to
the restoration of normal mitochondrial function (Alexeyev
et al., 2008). Similarly, using the heteroplasmic NZB/BALB
mouse model that carries two different mtDNA haplotypes
(NZB and BALB), BALB mtDNA, which contains a unique ApaLI
site, has been specifically reduced in vivo using a mitochon-
dria-targeted ApaLI (Bacman et al., 2012; 2010). Recently,
transcription activator-like effector nucleases (TALENs) and
zinc finger nucleases (ZFNs) targeted to mitochondria have
being utilized for the specific elimination of mitochondrial ge-
nomes carrying mutations responsible for mitochondrial dis-
eases (Bacman et al., 2013; Gammage et al., 2014; Minczuk
et al., 2006; 2008). These novel approaches allow for the
targeting of a wider spectrum of mutations against which re-
striction endonucleases could not be used. However, these
approaches do not provide mechanisms for preventing the
transmission of mutated mtDNA nor do they allow for a com-
plete systemic clearance of mtDNA mutations in subsequent
generations.
Here, we report on the specific reduction of mitochondrial
genomes in the germline for preventing transmission of mito-
chondrial diseases. As a proof of concept, and by using the het-
eroplasmic NZB/BALB mouse model, we specifically reduced
BALB or NZB mitochondrial genomes in the germline using
mitochondria-targeted restriction endonucleases and TALENs
and prevented their transmission to the next generation. More-
over, we successfully reduced mutated mitochondrial genomes
responsible for human mitochondrial diseases in mouse oo-
cytes using mitochondria-targeted nucleases. The approaches
presented here may be applied and developed to prevent
the transgenerational transmission of human mitochondrial
diseases.460 Cell 161, 459–469, April 23, 2015 ª2015 Elsevier Inc.RESULTS
Specific Reduction of Mitochondrial Genomes in
Oocytes and Embryos Using Restriction Endonucleases
With the goal of establishing an alternative therapeutic approach
for preventing the germline transmission of mitochondrial dis-
eases caused by mtDNA mutations, we tested the specific elim-
ination of BALB mtDNA in NZB/BALB oocytes and one-cell
embryos. For this purpose, we generated a mammalian codon
optimized ApaLI targeted to mitochondria by the ATP5B mito-
chondria targeting sequence and the ATP5B 50 and 30 UTRs to
promote co-translational import from mitochondrial associated
ribosomes (Marc et al., 2002). An enhanced GFP (EGFP) reporter
was also included in the construct to monitor expression (Fig-
ure 1A). First, we tested the mitochondrial localization of the
ApaLI protein generated from the construct by immunostaining
in NZB/BALB tail tip fibroblasts (TTFs) and observed robust
co-localization of mitochondria-targeted ApaLI (mito-ApaLI)
with the mitochondrial dye Mitotracker (Figure S1A). In contrast,
we failed to observe mitochondrial localization of non-mitochon-
dria-targeted ApaLI (Figure S1A). Analysis of mtDNA by ‘‘last-
cycle hot’’ PCR and restriction fragment length polymorphism
(RFLP) demonstrated induction of heteroplasmy shift by specific
reduction of BALB mtDNA in cells transfected with mito-ApaLI
compared to control cells transfected with mito-GFP after
72 hr (Figure S1B). In addition, we found normal mtDNA copy
number in mito-ApaLI transfected cells, which resulted from
the replication of the remaining NZB mtDNA that compensated
for the reduction of BALB mtDNA (Figure S1C).
We next decided to test whether a similar approach could be
used inoocytes tospecifically eliminateBALBmtDNA (Figure1A).
First, we confirmed the mitochondrial localization of mito-ApaLI
in NZB/BALBmetaphase II (MII) oocytes injected with mRNA en-
coding mito-ApaLI by immunostaining (Figure 1B). As expected,
mito-ApaLI co-localized with Mitotracker in MII oocytes (Fig-
ure 1B). RFLP analysis 48 hr after mito-ApaLI mRNA injection
demonstrated the specific reduction of BALB mtDNA and a
consequential increase in the relative NZB mtDNA levels (Fig-
ure1C). In agreementwith the lackofmtDNA replication inmature
oocytes andpre-implantation embryos (Wai et al., 2010), analysis
of mtDNA copy number by qPCR revealed a decrease in mtDNA
copy number following mito-ApaLI injection proportional to the
initial levels of BALB mtDNA (Figure 1D). To verify the reduction
of BALB mtDNA, we performed RFLP and qPCR analyses by
amplification of an independent region of the mtDNA containing
a unique HindIII site, exclusively present in BALB mtDNA. These
analyses confirmed the specific reduction of BALB mtDNA upon
injectionofmito-ApaLI inNZB/BALBMII oocytes (FigureS1Dand
S1E). Injection of mito-ApaLI in BALB or NZB single haplotype
oocytes resulted in complete depletion of mtDNA in BALB oo-
cytes and did not affect mtDNA levels in NZB oocytes reinforcing
the specificity of mito-ApaLI (Figure S1F). Collectively, these
results suggest the potential of this approach for the specific
reduction of mtDNA in the germline.
In addition to oocytes, we tested whether mtDNA hetero-
plasmy shift could be applied to one-cell embryos without
affecting their normal development until the blastocyst stage
(Figure 2A). For this purpose, NZB/BALB one-cell embryos
Figure 1. Heteroplasmy Shift in NZB/BALB
MII Oocytes Using mito-ApaLI
(A) Injection of mito-ApaLI mRNA in oocytes for
induction of heteroplasmy shift.
(B) Mitochondrial co-localization of mito-GFP and
mito-ApaLI with Mitotracker in injected oocytes by
immunofluorescence. Scale bars, 10 mm.
(C) RFLP analysis and quantification of mtDNA
heteroplasmy in control and mito-ApaLI injected
MII oocytes after 48 hr (Control n = 16; mito-ApaLI
n = 12). Representative gel.
(D) Quantification of mtDNA copy number by qPCR
in control and mito-ApaLI-injected oocytes MII
after 48 hr (Control n = 12; mito-ApaLI n = 12).
Error bars represent ± SEM. ****p < 0.0001. See
also Figure S1.were injected with mito-ApaLI mRNA. Time-lapse fluorescent
microscopy images revealed the expression of mito-ApaLI indi-
cated by EGFP expression, and more importantly, normal devel-
opment of mito-ApaLI-injected embryos through the different
developmental stages analyzed (Figure 2B). Similarly to the re-
sults observed in oocytes, RFLP analysis of mito-ApaLI blasto-
cysts demonstrated specific reduction of BALB mtDNA and an
increase in the relative levels of NZB mtDNA (Figure 2C). More-
over, due to the lack of mtDNA replication until the blastocyst
stage (Wai et al., 2010), analysis of mtDNA copy number by
qPCR showed a decrease in mtDNA levels proportional to the
BALB mtDNA levels (Figure 2D). RFLP and qPCR analyses at
the HindIII region confirmed the specific reduction of BALB
mtDNA upon injection of mito-ApaLI in NZB/BALB embryos
(Figures S2A and S2B).
Preventing the Transmission of Mitochondrial Genomes
Using Mitochondria-Targeted Restriction
Endonucleases
Next, we investigatedwhether induction ofmtDNA heteroplasmy
shift could be utilized for preventing the transmission of mito-Cell 161, 459–chondrial diseases to the next generation.
NZB/BALB one-cell embryos injected
with mito-ApaLI mRNA were cultured
in vitro until the blastocyst stage and
transferred to pseudopregnant mice (Fig-
ure 3A). After a standard gestation period,
pseudopregnant mice gave birth to live
pups through natural delivery (Figure 3B).
Most importantly, RFLP analysis of total
DNA from F1 mito-ApaLI animals re-
vealed a significant reduction of BALB
mtDNA (Figure 3C). Further analysis
demonstrated reduction of BALB mtDNA
in the brain, muscle, heart, and liver.
These data indicate the systemic clear-
ance of a specific mtDNA in the offspring
of heteroplasmic mothers (Figure 3D).
Similarly, analysis at the HindIII region
confirmed the specific reduction of
BALB mtDNA in F1 mito-ApaLI animals(Figures S3A and S3B). Furthermore, analysis of mtDNA copy
number showed normal mtDNA levels resulting from NZB
mtDNA replication upon embryo implantation (Figure 3E).
Comprehensive characterization of mito-ApaLI animals, both
males and females, showed normal development, weight gain
(Figure 4A), complete blood count (Table S1) as well as normal
blood levels of glucose and lactate, all potential indicators of
mitochondrial dysfunction (Haas et al., 2007) (Figure 4B). More-
over, typical behavioral studies indicative of CNS defects (Ross
et al., 2013), including open field, rotor-rod, grip strength, and
sensory neuron screening, showed normal performance of
mito-ApaLI animals (Figures 4C–4E).
To assess potential off-target effects on the nuclear genome,
we performed comparative hybridization genomic (CHG) array
and exome sequencing. CGH array indicated normal genomic
integrity of mito-ApaLI animals (Figure S3C). Confirming this
result, exome sequencing demonstrated variant rates in ApaLI
containing exomic regions comparable to non-ApaLI exomic re-
gions, excluding the possibility of off-target effects of mito-ApaLI
(0.0014 versus 0.0047 variants per hundred base pairs, respec-
tively). Furthermore, mito-ApaLI animals were fertile, and RFLP469, April 23, 2015 ª2015 Elsevier Inc. 461
Figure 2. Heteroplasmy Shift in NZB/BALB
Embryos Using mito-ApaLI
(A) Injection of mito-ApaLI mRNA in one-cell em-
bryos for induction of heteroplasmy shift.
(B) In vitro development of mito-ApaLI-injected
embryos to blastocyst stage. Time-lapse images
of EGFP reporter expression at different develop-
mental stages.
(C) RFLP analysis and quantification of mtDNA
heteroplasmy in control and mito-ApaLI-injected
embryos (Control n = 10; mito-ApaLI n = 8).
Representative gel.
(D) Quantification of mtDNA copy number by qPCR
in control and mito-ApaLI-injected embryos
(Control n = 18; mito-ApaLI n = 12).
Error bars represent ± SEM. ***p < 0.001. ****p <
0.0001. See also Figure S2.analyses showed barely detectable levels of BALB mtDNA in
the F2 generation (Figures 4F and S4). These results confirm
the feasibility of mtDNA heteroplasmy shift to prevent the trans-
generational transmission of mitochondrial diseases.
Preventing the Transmission of Mitochondrial Genomes
Using Mito-TALENs
Despite the broad range of over 200 mtDNA mutations associ-
ated with mitochondrial diseases, only the human mutation
m8993T>G responsible for two mitochondrial diseases: neuro-
genic muscle weakness, ataxia, and retinitis pigmentosa
(NARP) and maternally inherited Leigh syndrome (MILS) gener-
ates a unique restriction site that can be targeted using the
naturally occurring restriction endonuclease XmaI. For these rea-
sons, alternative approaches to induce heteroplasmy shift based
on the use of mitochondria-targeted transcription activator-like
effector nucleases (TALENs) and zinc finger nucleases (ZFNs),
which could be designed against virtually any mutation, have
been recently developed by us and other groups (Bacman
et al., 2013; Gammage et al., 2014; Minczuk et al., 2006;462 Cell 161, 459–469, April 23, 2015 ª2015 Elsevier Inc.2008). In order to evaluate the use of
mito-TALENs to prevent the transmission
of mitochondrial diseases, we tested the
specific elimination of NZB mtDNA in
NZB/BALB oocytes. For this purpose,
we first generated a collection of TALENs
against NZB mtDNA and screened for a
TALENwith the highest specificity against
NZB mtDNA (Figures S5A–S5C). Under
our design, the left monomer of the
TALEN will bind to the common sequence
of NZB and BALB mtDNA while the right
monomer will preferentially recognize
and bind to NZB mtDNA, dictating the
specific cleavage of NZB mtDNA upon
dimerization of the FokI nuclease (Fig-
ure S5A). NZB TALEN monomers were
targeted to mitochondria by the human
ATP5B and SOD2 mitochondria targeting
sequence and the ATP5B and SOD2 50and 30 UTRs to promote co-translational import from mitochon-
drial associated ribosomes (Marc et al., 2002). In addition, an
EGFP or mCherry reporter was also included in the constructs
encoding each TALEN monomer (Figure 5A). Once again, we
tested the mitochondrial localization of the NZB TALEN by
immunostaining in NZB/BALB tail tip fibroblasts (TTFs) and
observed robust co-localization of mitochondria-targeted
NZB TALEN monomers (hereafter NZB mito-TALEN) with the
Mitotracker (Figure S5D). Analysis of mtDNA by RFLP demon-
strated induction of heteroplasmy shift in NZB/BALB cells by a
specific reduction of NZB mtDNA after 72 hr in cells transfected
with NZB mito-TALENs compared to control cells transfected
with mito-GFP (Figure S5E). In addition, similar to mito-ApaLI,
we found normal mtDNA copy number in NZB mito-TALEN
transfected cells resulting from the replication of the remaining
BALB mtDNA that compensated for the reduction of NZB
mtDNA (Figure S5F).
We next decided to test whether mito-TALENs could be used
in oocytes to specifically eliminate NZBmtDNA (Figure 5A). Fluo-
rescent microscopy images revealed the expression of both
Figure 3. Generation of Live Animals after
Induction of Heteroplasmy Shift in NZB/
BALB Embryos Using mito-ApaLI
(A) Outline for the generation of live animals after
injection of mito-ApaLI mRNA in one-cell embryos.
(B) Representative photograph of F1 mito-ApaLI
mice.
(C) RFLP analysis and quantification of mtDNA
heteroplasmy in tail tip biopsies of embryo donors
and generated F1 mito-ApaLI pups. (Donor n = 10;
mito-ApaLI n = 9).
(D) RFLP analysis and quantification of mtDNA
heteroplasmy in tail, brain, muscle, heart, and liver
of F1 mito-ApaLI mice.
(E) Quantification of mtDNA copy number by qPCR
in F1 mito-ApaLI pups (Donor n = 10; F1 mito-
ApaLI n = 9).
Error bars represent ± SEM. ****p < 0.0001. See
also Figure S3.NZBmito-TALENmonomers as indicated by EGFP andmCherry
expression in oocytes (Figure 5B). RFLP analysis 48 hr after
NZB mito-TALEN mRNA injection demonstrated the specific
decrease of NZB mtDNA and a consequential increase in the
relative BALB mtDNA levels (Figure 5C). RFLP analysis at the
HindIII region confirmed the specific reduction of NZB mtDNA
upon injection of NZB mito-TALEN in NZB/BALB MII oocytes
(Figure S5G). Analysis of mtDNA copy number by qPCR revealed
a decrease in mtDNA copy number following NZB mito-TALEN
injection in oocytes in agreement with the lack of mtDNA replica-
tion in oocytes (Figure 5D). These results demonstrate the poten-
tial of custom designed mito-TALENs for the specific elimination
of mitochondrial genomes in the germline aimed at preventing
the transmission of mitochondrial diseases.
Specific Reduction of Human Mutated Mitochondrial
Genomes Responsible for Mitochondrial Diseases in
Mammalian Oocytes
In order to evaluate the potential of our approach to prevent the
transmission of human mitochondrial diseases we decided to
test the use ofmitochondria-targeted nucleases againstmutated
mitochondrial genomes responsible for two mitochondrial
diseases: Leber’s hereditary optic neuropathy and dystoniaCell 161, 459–(LHOND) and NARP (Jun et al., 1994; Tay-
lor and Turnbull, 2005). Due to the limited
number of available patients and the diffi-
culty in obtaining oocytes from these pa-
tients, we generated artificial mammalian
oocytes carrying mutated genomes by
cellular fusion of patient cells and mouse
oocytes using Sendai virus (Figure 6A).
Although this model has limitations
compared to patient oocytes, it helped
us to test the potential of ourmethodology
for the specific elimination of pathogenic
human mtDNAs in mammalian oocytes.
For this purpose, we first tested the
fusion of 143B osteosarcoma cybrid cellsharboring the LHOND m.14459G>A mutation to mouse MII oo-
cytes (Figure 6B). After 3 hr, complete fusion was observed
and no individual cells were detected under the zona pellucida
of oocytes (Figure 6B). LHOND-fused oocytes were incubated
for 48 hr and collected for analysis. PCR analysis using primers
specific against the humanmtDNA region containing the LHOND
m.14459G>A mutation allowed for the detection of LHOND
mtDNA in fused oocytes (Figure S6A). Next, we tested whether
the LHOND mito-TALEN that we have recently reported could
be used for the specific elimination of LHONDmtDNA in oocytes
(Bacman et al., 2013). For this purpose, MII oocytes harboring
LHOND mtDNA were injected with mRNA encoding the LHOND
mito-TALEN 3 hr after cell fusion. Fluorescent microscopy
images revealed the expression of both LHOND mito-TALEN
monomers as indicated by EGFP and mCherry expression (Fig-
ure S6B). RFLP analysis 48 hr after mRNA injection demon-
strated the specific reduction of LHONDmtDNA in fused oocytes
(Figure 6C). Analysis of mtDNA copy number by qPCR confirmed
a significant reduction of human mutated LHOND mtDNA upon
injection of LHOND mito-TALENs in fused oocytes (Figure 6D).
Finally, to demonstrate the potential of this approach against
other mitochondrial diseases we decided to use a similar strat-
egy to test the elimination of human mitochondrial genomes469, April 23, 2015 ª2015 Elsevier Inc. 463
Figure 4. Characterization of F1 mito-ApaLI Mice
(A) Body weight of mito-ApaLI males (Control n = 5 and mito-ApaLI n = 3) and mito-ApaLI females (Control n = 5 and mito-ApaLI n = 6) at different time points. ns,
non-significant.
(B) Biochemical analysis of glucose and lactate in blood of control (n = 10) and mito-ApaLI (n = 9) mice. ns, non-significant.
(C) Open field test measuring baseline levels of locomotor activity in freely moving mice quantifying distance traveled, ambulatory counts, and vertical counts.
(D) Rotarod test evaluating locomotor coordination based on the latency at which a fall occurs on a gradually accelerating spinning rod.
(E) Grip strength test measuring average and maximum grip force in the forelimbs.
(F) RFLP analysis and quantification of mtDNA heteroplasmy in tail tip biopsies of F2 mito-ApaLI pups. (F2 mito-ApaLI n = 12).
Error bars represent ± SEM. See also Figure S4 and Table S1.
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Figure 5. Heteroplasmy Shift in NZB/BALB
MII Oocytes Using NZB Mito-TALEN
(A) Injection of NZB mito-TALEN mRNA in oocytes
for induction of heteroplasmy shift.
(B) Expression of fluorescent reporters of NZB
TALEN monomer in MII oocytes.
(C) RFLP analysis and quantification of mtDNA
heteroplasmy in control and NZB TALEN-injected
oocytes after 48 hr (Control n = 9; NZB TALEN
n = 7). Representative gel.
(D) Quantification of mtDNA copy number by qPCR
in control and NZB TALEN-injected oocytes after
48 hr (Control n = 16; NZB TALEN n = 8).
Error bars represent ± SEM. **p < 0.01. ***p <
0.001. See also Figure S5.carrying the mutation NARP m.9176T>C. For this purpose, we
first generated a collection of TALENs against NARP mtDNA
and screened for a TALEN with the highest specificity against
the mutation NARP m.9176T>C (Figures S6C–S6E). NARP
mito-TALEN monomers were targeted to mitochondria by the
ATP5B and SOD2 mitochondria targeting sequence and the
ATP5B and SOD2 50 and 30 UTRs (Figure 6A). Immunostaining
in NARP patient cells revealed a robust co-localization of mito-
chondria-targeted NARP mito-TALEN monomers with the mito-
chondrial dye Mitotracker (Figure S6F). Subsequently, we tested
the induction of heteroplasmy shift by NARP mito-TALEN using
immortalized NARP patient cells. Analysis of mtDNA by RFLP
demonstrated induction of heteroplasmy shift in NARP cells
with a reduction in NARP mtDNA after 72 hr in cells transfected
with the NARP mito-TALEN compared to cells transfected with
mito-GFP (Figure S6G). In addition, we found normal mtDNA
copy numbers in NARP mito-TALEN transfected cells resulting
from the replication of the remaining mtDNA (Figure S6H).
Next, similar to LHOND, we tested the specific elimination ofCell 161, 459–NARPmitochondrial genomes in oocytes.
As before, patient cells harboring the
NARP m.9176T>C mutation were fused
to MII oocytes using Sendai virus and in-
jected with NARP mito-TALEN 3 hr after
fusion. Fluorescent reporters for both
NARP mito-TALEN monomers were
observed in oocytes as indicated by
EGFP and mCherry expression (Fig-
ure S6I). RFLP analysis 48 hr after
mRNA injection demonstrated the spe-
cific reduction of NARP mtDNA in fused
oocytes (Figure 6E). Analysis of mtDNA
copy number by qPCR confirmed a signif-
icant reduction of human mutated NARP
mtDNA upon injection of NARP mito-
TALENs in fused oocytes (Figure 6F). We
speculate that the low levels of wild-type
mtDNA carried by the NARP patient cells,
together with the lack of mtDNA replica-
tion in oocytes, might be the reason why
we fail to detect a significant increase in
wild-type human mtDNA upon NARPmito-TALEN injection. Collectively, these results confirm the po-
tential of custom-designedmito-TALENs for the specific elimina-
tion of clinically relevant mutated mitochondrial genomes
responsible for human mitochondrial diseases in the germline.
DISCUSSION
In summary, we report here on novel strategies for preventing
germline transmission of mitochondrial diseases through the in-
duction of mtDNA heteroplasmy shift in oocytes and embryos.
Asaproofof concept,weusedaheteroplasmicmousemodel car-
rying two different mtDNA haplotypes: NZB and BALB. First, we
demonstrated that injection ofmRNA encodingmitochondria-tar-
geted ApaLI restriction enzyme into oocytes, as well as into one-
cell embryos, led to thegenerationof live animalswith significantly
reduced levels of theBALBmtDNAhaplotype. These animals dis-
played normal behavior, development, gross genomic integrity
and fertility. Moreover, their progeny (F2 generation) maintained
significantly reduced levels of BALB mtDNA. These results469, April 23, 2015 ª2015 Elsevier Inc. 465
Figure 6. Specific Elimination of Human
LHOND m.14459G>A and NARP m.9176T>C
Mutations in Mammalian Oocytes Using
Mito-TALENs
(A) Fusion of human cells harboring LHOND
m.14459G>A and NARP m.9176T>C mutations
with mouseMII oocytes followed by the injection of
mito-TALENs for induction of heteroplasmy shift.
(B) Representative images of MII oocytes before
and after cell fusion.
(C) RFLP analysis and quantification of LHOND
heteroplasmy in individual MII oocytes with and
without LHOND TALEN injection after 48 hr (Fusion
n = 3; Fusion + TALEN n = 3).
(D) Quantification of human mtDNA copy number
by qPCR in individual MII oocytes with and without
LHOND TALEN injection after 48 hr (Fusion n = 4;
Fusion + TALEN n = 4).
(E) RFLP analysis and quantification of NARP
heteroplasmy in individual MII oocytes with and
without NARP TALEN injection after 48 hr (Fusion
n = 7; Fusion + TALEN n = 3).
(F) Quantification of human mtDNA copy number
by qPCR in individual MII oocytes with and without
NARP TALEN injection after 48 hr (Fusion n = 17;
Fusion + TALEN n = 9).
Error bars represent ± SEM. *p < 0.05. ***p < 0.001.
See also Figure S6.demonstrate the potential of germline heteroplasmy shift to pre-
vent the transgenerational transmission of mitochondrial ge-
nomes. Inaddition, injectionofmRNAencodingmitochondria-tar-
getedNZBmito-TALEN into oocytes led to a significant reduction
of NZB mtDNA levels. Finally, fusion of human patient cells car-
rying mtDNA mutations to mouse oocytes followed by injection
ofmito-TALENs against thesemutations demonstrated a specific
reduction in the levels of mutated mtDNA.
The use of restriction nucleases for the induction of hetero-
plasmy shift has been previously demonstrated in the NZB/
BALB mouse as well as in patient somatic cells by us and other
groups (Alexeyev et al., 2008; Bacman et al., 2010; 2012). How-
ever, the application of restriction enzymes to target clinically
relevant mutations is limited to only m8993T>G, which is respon-
sible for some cases of NARP and MILS, a mutation that gener-
ates a unique restriction site that can be targeted using the
restriction endonuclease XmaI (Alexeyev et al., 2008). The use
of other approaches using different types of nucleases including
TALENsmight allow for the custom-designed targeting of awider
range of human mitochondrial mutations responsible for mito-466 Cell 161, 459–469, April 23, 2015 ª2015 Elsevier Inc.chondrial diseases. Along this line, several
reports have recently demonstrated the
use of mitochondria-targeted TALENs
and zinc finger nucleases (ZFNs) for the
specific elimination of mutated mitochon-
drial genomes in somatic cells (Bacman
et al., 2013; Gammage et al., 2014; Min-
czuk et al., 2006; 2008). When compared
to mitochondria-targeted restriction en-
donucleases, the use of mito-TALENs forpreventing transmission of mitochondrial diseases in the germ-
line may be less robust. However, we speculate that their thera-
peutic use will achieve specific reduction of mutated mitochon-
drial genomes below the threshold levels (60%–95%) required
for biochemical and clinical defects to manifest (Russell and
Turnbull, 2014). In addition, we anticipate that the future develop-
ment and application of more specific and efficient gene editing
technologies will allow for a greater reduction of mutatedmtDNA
levels in the germline.
Transmission of mitochondrial diseases by female carriers
directly correlates with the levels of mutated mtDNA present in
oocytes. Inmany cases, asymptomatic female carrierswith inter-
mediate levels ofmutant loadmay produce oocyteswith different
ranges of mutated mtDNA (Chinnery et al., 2000; Cree et al.,
2009). Due to the lack of mtDNA replication in oocytes and pre-
implantation embryos, targeting of mutated mtDNA in oocytes
with high mutant loads using the approach presented here may
lead to adramatic reduction inmtDNAcopy number. Inmice, em-
bryos with mtDNA levels below a specific threshold develop nor-
mally during the pre-implantation stages but subsequently fail to
implant in the uterus or undergo development arrest (Wai et al.,
2010). Consequently, oocytes containing high levels of mutated
mtDNA that are subjected to heteroplasmy shiftmay result in em-
bryoswith lowmtDNA copy number that may fail to implant in the
uterinewall. In this case, thoughheteroplasmyshiftmaynot result
in a viable embryo, it would attain the goal of hampering the
development and implantation of embryos with high mutant
loads, thereby preventing the transmission of mitochondrial dis-
eases to the next generation. In this scenario, PGD could be used
as a complementary approach to select embryos with mtDNA
copy numbers sufficient for implantation.
Due to the non-Mendelian segregation of mtDNA, current
therapeutic approaches, including genetic counseling and
PGD, can only partially reduce, but not eliminate, the risk of
transmission of mitochondrial diseases (Brown et al., 2006).
The recent development of mitochondrial replacement tech-
niques based on spindle, pronuclear, or polar body transfer
into healthy enucleated donor oocytes or embryos, soon to
be allowed in the UK and currently under review by US regu-
latory agencies, represent a valid and powerful alternative
to current approaches (Craven et al., 2010; Paull et al., 2013;
Tachibana et al., 2013; Wang et al., 2014). Mitochondrial
replacement techniques involve a series of complex technical
manipulations of nuclear genome between patient and donor
oocytes that will result in the generation of embryos carrying
genetic material from three different origins. For these
reasons, mitochondrial replacement techniques have raised
biological, medical, and ethical concerns (Hayden, 2013; Rein-
hardt et al., 2013). Despite their great potential, more studies
are still required to show that these techniques are safe in hu-
man oocytes. The approach presented here relies on a single
injection of mRNA into patient oocytes, which is technically
simpler and less traumatic to the oocyte compared to mito-
chondrial replacement techniques (Craven et al., 2010; Paull
et al., 2013; Tachibana et al., 2013; Wang et al., 2014). Impor-
tantly, it does not require healthy donor oocytes, thus avoiding
ethical issues related to the presence of donor mtDNA.
Induction of mtDNA heteroplasmy shift using restriction endo-
nucleases or TALENs has the potential to eliminate mutated
mitochondrial genomes in the germline, and consequently, pre-
vent the transgenerational transmission of mitochondrial dis-
eases. In addition, since mtDNA mutations in the germline
have been recently linked to aging (Ross et al., 2013), this strat-
egy could also be applied to prevent the transmission of mtDNA
variants with potential roles in aggravating aspects of human ag-
ing and age-associated diseases.EXPERIMENTAL PROCEDURES
Plasmids
A synthetic gene coding for the ApaLI restriction endonuclease with a C-termi-
nal HA (Hemagglutinin antigen) tag was purchased from Integrated DNA Tech-
nologies (Coralville) with codon usage optimized for mammalian translation.
For the generation of the mito-ApaLI construct, ApaLI was subcloned into
the pVAX plasmid containing the mitochondria localization signal derived
from ATP5B, a unique Flag immunotag in the N terminus, 50 and 30 UTR from
ATP5B to localize the mRNA to ribosomes associated with mitochondria, an
independent fluorescent marker to select for expression (enhance GFP
[EGFP]) and a recoded picornaviral 2A-like sequence (T2A0) between themito-ApaLI and the fluorescent marker. Subsequently, the fragment described
was subcloned into the pcDNA3 plasmid containing a T7 promoter for in vitro
transcription. For the generation of the mito-GFP construct, EGFP was subcl-
oned into the previously described pVAX construct lacking the independent
fluorescent marker and the recoded picornaviral 2A-like sequence (T2A0) but
containing a T7 promoter. For the generation of ApaLI construct, ApaLI RE
was subcloned into the previously described pVAX plasmid lacking the N ter-
minus mitochondria localization signal derived from ATP5B and the 50 and 30
UTRs from ATP5B with a T7 promoter. Cloning was done using the In-Fusion
HD cloning kit (Clontech Laboratories).
Construction of Mito-TALENs
TALEN target sites for NZB and NARP m.9176T>C were identified using the
TAL effector-Nucleotide Targeter (TALE-NT) software (Christian et al., 2010).
To increase TALEN specificity, TALEN with targeting sequences of various
lengths ranging from 7.5 to 13.5 base pairs were designed. TALENs were con-
structed into the TALEN cloning vector of the TALE Toolbox kit from Addgene
(cat#1000000019) (Sanjana et al., 2012), and the TALENs recognizing the
target sites were constructed using the Golden Gate Assembly method.
Mito-TALEN, were constructed by addition of mitochondria localization
signals derived from ATP5B or SOD2 mitochondria localization signal, inclu-
sion of a unique immuno-tag in the N terminus of the mature protein (hemag-
glutinin [HA] or Flag), inclusion of the 50 and 30 UTRs from ATP5B or SOD2,
inclusion of an independent fluorescent marker to select for expression
(EGFP in one monomer and mCherry in the other) and inclusion of a recoded
picornaviral 2A-like sequence (T2A0) between the mito-TALEN and the fluores-
cent marker.
Animals
All animal procedures were performed according to NIH guidelines and
approved by the Committee on Animal Care at Salk Institute. NZB/BALB het-
eroplasmic founder females were originally generated (Jenuth et al., 1996).
NZB/BALB colony was maintained by breeding the females with BALB/cByJ
males. Tail tip genotyping was routinely performed in order to exclude females
carrying low levels of one of the two mtDNA haplotypes. BALB/c, BALB/cByJ
and NZB mice were obtained from Jackson laboratory.
Cells, Transfection, and Sorting
Simian virus 40 (SV40) immortalizedNZB/BALBfibroblasts containingNZBand
BALBmtDNAwere derived from tail tip ofNZB/BALBmice.Humanpatient cells
harboring the NARP m.9176T>C mutation were obtained by skin biopsy after
signed informed consent of the donor and with the approval of the Institutional
ReviewBoard of theHospital Clinic, Spain. Cells were immortalized using SV40
and cultured at 37 C in DMEM (Invitrogen) containing GlutaMAX, non-essen-
tial amino acids and 10% fetal bovine serum (FBS). 143B osteosarcoma cybrid
cells harboring the LHONDm.14459G>Amutation were obtained and cultured
as previously described (Bacman et al., 2013). Cells were transfected with Lip-
ofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Af-
ter 72 hr, cells were sorted using a BD Influx (Becton, Dickinson and Company)
bygatingon single-cell fluorescence using a488-nm laserwith a 505LP, 530/40
filter set for EGFP and a 561-nm laser with a 600LP, 610/20 filter set for
mCherry. Total DNA was extracted from sorted cells using the DNeasy Blood
andTissueKit (QIAGEN) following the protocol suggestedby themanufacturer.
Single Strand Annealing Reporter Assay
Please refer to Extended Experimental Procedures.
Production of mRNA
In vitro transcription of mRNA was performed using mMESSAGE mMACHINE
T7 ULTRA kit (Life Technologies) according to the manufacturer’s instructions
using linearized and gel purified (QIAGEN) plasmid template. The mRNA was
purified using MEGAclear kit (Life Technologies) and quantified using Nano-
Drop 8000 (Thermo Scientific).
Oocyte Collection and mRNA Injection
Female mice were superovulated with pregnant mares serum gonadotropin
(PMSG) and human chorionic gonadotropin (hCG). MII oocytes wereCell 161, 459–469, April 23, 2015 ª2015 Elsevier Inc. 467
collected 14 hr after hCG injection in M2 medium (Millipore) and freed of
cumulus cells using hyaluronidase. For collection of 1-cell embryos, supero-
vulated female mice were mated to BALB/c males and fertilized embryos
were collected 18–20 hr after hCG injection from oviduct. mRNA (50–
250 ng/ml) was injected into the cytoplasm of MII oocytes and fertilized
embryos in M2 medium using Eppendorf micromanipulator. The injected
MII oocytes were in vitro cultured in KSOM (Millipore) for 48 hr before anal-
ysis. The injected embryos were cultured in KSOM at 37C under 5% CO2
in air until blastocyst stage. Subsequently, blastocysts were collected for
analysis or transferred to BALB/c pseudopregnant females. Live pups were
obtained by natural delivery.
Cell Fusion
Cell fusion was achieved by using inactivated Sendai virus (GenomeOne,
Cosmo Bio). Sendai virus stock solutions were prepared according to
the manufacturer instructions and further diluted 1:20 in cell fusion buffer.
The 143B osteosarcoma cybrid cells harboring LHON m.14459G>A
mutation and patient cells harboring NARP m9176T>C mutation were used
for fusion with mature MII oocytes. Cells were cultured for 48 hr in DMEM no
glucose medium supplemented with galactose before using for cell fusion to
increase mtDNA content. On the day of fusion, cells were trypsinized and re-
suspended inM2medium. For eachMII oocyte, five cells briefly placed in Sen-
dai virus were injected under the zona pellucida. After 3 hr successfully fused
oocytes were selected for mito-TALEN mRNA injection. Lastly, surviving oo-
cytes were cultured in KSOM for 48 hr before analysis.
Immunofluorescence
Cells were seeded on coverslips before transfection. Forty-eight hours after
transfection cellswere incubated in thepresence of 350 nMMitotracker (Invitro-
gen) for 30min. Subsequently, cells were fixed and permeabilized with 4%PFA
and 0.1%Triton X-100, respectively. After fixation, cells were blocked for 1 hr at
room temperature with 1% BSA/PBS. Next, cells were incubated with an anti-
Flag M2 primary antibody (Sigma) or anti-HA antibody (Millipore) overnight at
4C. The next day, cells were washed three times with PBS and incubated for
1 hr at room temperature with Alexa Fluor 488-conjugated donkey antibodies
togoat IgG (MolecularProbes) orAlexaFluor647-conjugateddonkeyantibodies
to mouse IgG and 10 min with Hoechst 33342 (0.5 mg ml1 in PBS) (Invitrogen).
Finally, cells were washed three times with PBS and mounted using Fluoro-
mount-G (Southernbiotech). Confocal image acquisition was performed using
a Zeiss LSM 780 laser-scanning microscope (Carl Zeiss Jena).
‘‘Last-Cycle Hot’’ PCR and RFLP
Total DNA from cells, tail biopsies, and oocytes/embryos were used to
determine mtDNA heteroplasmy by ‘‘Last-cycle hot’’ PCR using the mtDNA
50 Fluorescein amidite (FAM) labeled primers as listed in Table S2. NZB/
BALB PCR products were digested with ApaLI or HindIII, which digests
BALB mtDNA at positions 5461 (ApaLI targeting site) and 9136 respectively.
NARP PCR products were digested with BsrI which digest mutated
NARP mtDNA at position 9176. The levels of LHON m.14459G>A were
determined as previously reported (Bacman et al., 2013). Digested PCR
products were subjected to electrophoresis in an 12% polyacrylamide
gel. The fluorescein signal was quantified using a Typhoon 8600 system
(Molecular Dynamics) and gels were quantified using ImageQuant 5.2
(Molecular Dynamics).
Quantification of mtDNA Copy Number
Absolute mtDNA copy numbers were quantified by real-time PCR using
iQSyber Green on Bio-Rad iCycler (Bio-Rad). Individual oocytes and em-
bryos were transferred into lysis buffer (200 mM KOH) and incubated for
10 min at 65C. The reaction was neutralized by addition of 200 mM HCl.
Absolute mtDNA copy number per 1 ml of lysate was calculated using a stan-
dard curve derived from the Q-PCR amplification of a fragment of mtDNA
genome. First, a standard curve was generated by a 10-fold serial dilution
of a PCR product obtained using Standard curve primers for the different
regions of mtDNA analyzed. Subsequently, to quantify the absolute levels
of mtDNA, quantitative real-time PCR was performed using qPCR primers
listed in Table S2.468 Cell 161, 459–469, April 23, 2015 ª2015 Elsevier Inc.Blood and Plasma Parameters
Bloodcollectionwasperformedbysub-mandibularbleeding.WholeEDTAblood
samples were analyzed in duplicates for Complete Blood Count (CBC) on
a Hemavet 950FS Multi Species Hematology System (Drew Scientific). Plasma
glucoseconcentrationwasdeterminedusing theGlucose (GO)AssayKit (Sigma)
according to the manufacturer’s instructions. Plasma lactate concentration was
determined using the Lactate AssayKit (Sigma) according to themanufacturer’s
instructions. Please refer to Extended Experimental Procedures.
Behavioral Analysis
Behavioral testing was carried out at the Salk Institute for Biological Studies
Behavioral Testing Core. Basic sensorimotor function was assessed in the
Open Field Test, Rotarod, Grip Strength, and Neurological Screen. Please
refer to Extended Experimental Procedures.
Array Comparative Genomic Hybridization
aCGH was performed following Agilent Oligonucleotide Array-Based CGH for
Genomic DNAAnalysis (Agilent Technologies, Santa Clara, CA). Please refer to
Extended Experimental Procedures.
Exome Capture and High-Throughput Sequencing
Exome capture was using the SeqCap EZ Mouse Exome Design probe pool
(54 Mb, NimbleGen) according to the manufacturer’s protocol. Please refer
to Extended Experimental Procedures.
Statistical Evaluation
Statistical analyses were performed by using standard unpaired Student’s t
test with Welch’s correction using Prism 6 software (GraphPad). All data are
presented as mean ± SEM and represent a minimum of two independent
experiments. Statistical significance is displayed as *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001.
ACCESSION NUMBERS
The GEO database accession number for the aCGH data sets reported in this
paper is GSE67371. The GEO accession number for the exome sequencing
data sets reported in this paper is SRP056327.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2015.03.051.
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